Allogenic benefit in stem cell therapy: cardiac repair and regeneration
Stem cell (SC)‐based therapies are a developing mean to repair, restore, maintain, or enhance organ functioning through life span. They are in particular a fast track to restore function in failing heart. Various types of SCs have been used in experimental and clinical studies showing the potential...
Saved in:
Published in | Tissue antigens Vol. 86; no. 3; pp. 155 - 162 |
---|---|
Main Authors | , |
Format | Journal Article |
Language | English |
Published |
Oxford, UK
Blackwell Publishing Ltd
01.09.2015
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | Stem cell (SC)‐based therapies are a developing mean to repair, restore, maintain, or enhance organ functioning through life span. They are in particular a fast track to restore function in failing heart. Various types of SCs have been used in experimental and clinical studies showing the potential of these cells to revolutionize the treatment of heart diseases. Autologous cells have been privileged to overpass immunological barriers. The field has progressed tremendously and the hurdles, which have been largely overlooked in the excitement over the expected benefit the immunogenicity, have been revealed. Also, manufacturing of patient‐specific clinical grade SC product, whether adult stem or reprogrammed induced pluripotent SCs, and the availability of these cells in sufficient amounts and status when needed is questionable. In contrast, adult SCs derived from healthy donors, thus allogeneic, have the advantage to be immediately available as an ‘off‐the‐shelf’ therapeutic product. The challenge is to overcome the immunological barriers to their transplantation. Recent research provided new insights into the mode of action and immune behavior of SCs in autologous as well as allogeneic settings. Lessons are learned and immune paradigms are changing: allogenicity, if balanced could be part of the dynamic and durable mechanisms that are critical to sustain cardiac regeneration and repair. We discuss the hurdles, lessons, and advances accomplished in the field through the progressive journey of cardiac‐derived stem/progenitor cells toward allogeneic cardiac regenerative/reparative therapy. |
---|---|
Bibliography: | istex:F62B29FDA8146ABA1467239D76494BC1B1340AB1 INSERM grants LABEX TRANSPLANTEX - No. ANR-11-LABX-0070 HLA et Medicine European grant - No. FP7-HEALTH-2009-1.4-3 ArticleID:TAN12614 ark:/67375/WNG-JCF2JKQ2-H ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-3 content type line 23 ObjectType-Review-1 |
ISSN: | 0001-2815 1399-0039 |
DOI: | 10.1111/tan.12614 |